Clinical Trial Results:
A randomized, parallel-group, double-blind, placebo-controlled, multicenter phase III study to investigate the efficacy and safety of secukinumab (Cosentyx) 300 mg administered subcutaneously in patients with active peripheral spondyloarthritis (pSpA)
Summary
|
|
EudraCT number |
2021-001256-34 |
Trial protocol |
SK IT HU ES DE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
10 May 2024
|
First version publication date |
10 May 2024
|
Other versions |
|
Summary report(s) |
Novartis_cancel study summary attachment_CAIN457X12301 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.